Payment overview · 2025
General Payments
$274.97
14 reported records · 9 companies
Healthcare provider profile · identity verified
Amy C James, MD
Allopathic & Osteopathic Physicians|Family Medicine · MARSHALL, IL · NPI 1972549426
Verified facts
What the public records show
CMS Open Payments records show Amy C James, MD received $274.97 in general payments during 2025 across 14 reported records.
Lilly USA, LLC accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Mounjaro, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 446 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 446 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.45 | 20.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.03 | 13.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.34 | 12.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.13 | 12.4% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.93 | 12.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.18 | 8.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.41 | 7.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.26 | 6.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.24 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $274.97 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $61.14 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.03 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $35.34 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $35.34 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.13 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $32.93 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 29 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 446 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 186 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
446 | 64 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
78 | 63 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
446 | 64 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
186 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
78 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1000 | 220 |
| Levothyroxine Sodium | Levothyroxine Sodium | 803 | 146 |
| Omeprazole | Omeprazole | 549 | 133 |
| Lisinopril | Lisinopril | 517 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 510 | 111 |
| Furosemide | Furosemide | 509 | 119 |
| Gabapentin | Gabapentin | 471 | 80 |
| Jardiance | Empagliflozin | 446 | 64 |
| Eliquis | Apixaban | 420 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 396 | 82 |
| Duloxetine Hcl | Duloxetine Hcl | 395 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 372 | 81 |
| Sertraline Hcl | Sertraline Hcl | 363 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 359 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 347 | 75 |
| Losartan Potassium | Losartan Potassium | 337 | 75 |
| Potassium Chloride | Potassium Chloride | 329 | 73 |
| Famotidine | Famotidine | 265 | 64 |
| Metformin Hcl | Metformin Hcl | 261 | 61 |
| Carvedilol | Carvedilol | 250 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 250 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 248 | 49 |
| Xarelto | Rivaroxaban | 238 | 26 |
| Lorazepam | Lorazepam | 231 | 55 |
| Trazodone Hcl | Trazodone Hcl | 230 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 219 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 186 | 42 |
| Mounjaro | Tirzepatide | 186 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 182 | 53 |
| Allopurinol | Allopurinol | 172 | 38 |
| Alprazolam | Alprazolam | 168 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 167 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 166 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 155 | 27 |
| Clonazepam | Clonazepam | 151 | 26 |
| Mirtazapine | Mirtazapine | 149 | 27 |
| Meloxicam | Meloxicam | 145 | 41 |
| Pregabalin | Pregabalin | 142 | 27 |
| Tramadol Hcl | Tramadol Hcl | 142 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 134 | 32 |
| Alendronate Sodium | Alendronate Sodium | 128 | 31 |
| Metformin Hcl Er | Metformin Hcl | 125 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 28 |
| Donepezil Hcl | Donepezil Hcl | 120 | 25 |
| Montelukast Sodium | Montelukast Sodium | 119 | 27 |
| Simvastatin | Simvastatin | 118 | 31 |
| Cephalexin | Cephalexin | 114 | 63 |
| Levetiracetam | Levetiracetam | 110 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 107 | 15 |
| Buspirone Hcl | Buspirone Hcl | 104 | 19 |
| Nystatin | Nystatin | 103 | 36 |
| Memantine Hcl | Memantine Hcl | 101 | 16 |
| Spironolactone | Spironolactone | 98 | 23 |
| Finasteride | Finasteride | 96 | 21 |
| Ondansetron Odt | Ondansetron | 96 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 95 | 23 |
| Farxiga | Dapagliflozin Propanediol | 94 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 24 |
| Olanzapine | Olanzapine | 91 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 90 | 20 |
| Warfarin Sodium | Warfarin Sodium | 88 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 86 | 18 |
| Bupropion Xl | Bupropion Hcl | 81 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 15 |
| Entresto | Sacubitril/Valsartan | 78 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 78 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 16 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 76 | 76 |
| Amitriptyline Hcl | Amitriptyline Hcl | 74 | 13 |
| Ibuprofen | Ibuprofen | 74 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 74 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 72 | 12 |
| Lovastatin | Lovastatin | 72 | 19 |
| Bumetanide | Bumetanide | 71 | 14 |
| Trulicity | Dulaglutide | 71 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 70 | 15 |
| Ozempic | Semaglutide | 70 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 20 |
| Nifedipine Er | Nifedipine | 69 | 14 |
| Novolog Flexpen | Insulin Aspart | 69 | 15 |
| Risperidone | Risperidone | 69 | suppressed |
| Prednisone | Prednisone | 68 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 21 |
| Incruse Ellipta | Umeclidinium Bromide | 66 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 13 |
| Midodrine Hcl | Midodrine Hcl | 63 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 61 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 60 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 59 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 39 |
| Glipizide | Glipizide | 57 | 15 |
| Myrbetriq | Mirabegron | 57 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 41 |
| Latanoprost | Latanoprost | 55 | suppressed |
| Sucralfate | Sucralfate | 55 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 32 |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Fluconazole | Fluconazole | 51 | 34 |
| Synthroid | Levothyroxine Sodium | 51 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 48 | suppressed |
| Amoxicillin | Amoxicillin | 47 | 32 |
| Atenolol | Atenolol | 47 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 47 | suppressed |
| Loperamide | Loperamide Hcl | 45 | 20 |
| Diazepam | Diazepam | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 12 |
| Clozapine | Clozapine | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 16 |
| Tradjenta | Linagliptin | 41 | suppressed |
| Methylprednisolone | Methylprednisolone | 40 | 38 |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Metolazone | Metolazone | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 38 | 13 |
| Rybelsus | Semaglutide | 38 | 13 |
| Galantamine Hbr | Galantamine Hbr | 37 | suppressed |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Celecoxib | Celecoxib | 34 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 32 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 29 | 29 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 29 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 27 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 27 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Insulin Lispro | Insulin Lispro | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Budesonide | Budesonide | 25 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 18 |
| Admelog Solostar | Insulin Lispro | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 23 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Lubiprostone | Lubiprostone | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 16 |
| Folic Acid | Folic Acid | 21 | suppressed |
| Novolog | Insulin Aspart | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 19 | 11 |
| Daptomycin | Daptomycin | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Probenecid | Probenecid | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Cefdinir | Cefdinir | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Valproic Acid | Valproic Acid | 15 | suppressed |
| Xtampza Er | Oxycodone Myristate | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Unithroid | Levothyroxine Sodium | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Meropenem | Meropenem | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $274.97 · 14 records | Lilly USA, LLC | AREXVY, Auvelity, Cologuard Collection Kit, Dexcom G6 Transmitter, JARDIANCE, LEQVIO, MOUNJARO, Ozempic, PENMENVY, SHINGRIX, VRAYLAR, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error